XEsearch Clinical

We deliver speedy research start-up deadlines, on-time deliveries, proactive risk management, and high-quality data as your cardiovascular CRO, all while staying within budget. We recognize that tiny biotech enterprises require a partner who can supplement their limited workforce while also being mindful of budget constraints.

We have a professional team with years of experience in medical leadership, project management, and clinical operations who can carry out endocrinology studies using proven effective methodologies, no matter where they are conducted or what the indication is. This results in faster study start-up times, on-time deliverables, proactive risk management, and high-quality data delivery, all while staying under budget.

Our gastroenterology and herpetology specialists are well-versed in a wide range of digestive disorders.

In the United States alone, gastrointestinal illnesses impact an estimated 60-70 million individuals each year. 1 Novel therapeutics in gastroenterology and hepatology are critically needed around the world. We have a specialist gastroenterology/herpetology team of 800 people who are familiar with a wide range of digestive problems.

Because of the rise in immunologic and inflammatory disorders, as well as the creation of targeted medications, it is important to get novel products to market as quickly as possible while maintaining quality in a highly competitive research environment.

Our extensive worldwide and local expertise in autoimmune and inflammatory disease research is unrivaled. We have a large global network of facilities as well as experienced clinical research teams. Our therapeutic experts and validated processes, as well as our extensive training programs, are critical components in ensuring excellent data quality.

The power of infectious disease and vaccine research to have a broad impact on public health is unparalleled. Every member of Syneos Health’s Infectious Disease business segment is dedicated to furthering this essential work.

True therapeutic alignment provides us with not only an unrivaled depth and breadth of expertise among our best-in-class infectious disease study teams, but also deep partnerships with well-known and trusted sites and investigators around the world – relationships that are always important, but are especially critical during fast-moving outbreaks.

An aging global population, alongside unmet ocular illness demands that have real-world implications for quality of life, has sparked a surge of interest and opportunity in creating new eye disease treatments. Ophthalmology research is extremely specialized, requiring in-depth understanding of the patient and caregiver experience, long-term relationships with reputable research sites, and technical expertise in ocular imaging and a variety of treatment methods.

Chronic respiratory diseases remained the major cause of morbidity in 2017 in the world. Asthma and COPD were found to be responsible for a significant amount of the illness burden1. Between 1990 and 2017, the number of cases of interstitial lung disease and pulmonary sarcoidosis approximately doubled.

Rare lung disorders impact at least 1.2–2.5 million American patients and 1.3–3 million European patients2. Over the last decade, the medical world has become increasingly interested in conducting linked respiratory clinical studies, as well as substantial advancements in the field of uncommon diseases2.

XEsearch is a big supporter of biopharmaceutical businesses working on new women’s health solutions. The following are some of our areas of expertise:

Since 2013, 86 women’s health clinical trials have been successfully designed, implemented, and executed, treating 46,800 patients at 5,240 sites around the world. Since 2013, 14 studies with a fertility focus have been successfully designed, implemented, and executed, treating 7,726 patients at 373 sites around the world.

XEsearch is well-known for its pain management work, which includes the design, feasibility, execution, analysis, and interpretation of studies in a variety of acute, subacute, and chronic pain problems, as well as unusual indications and pediatric pain.

Multiple medications and personalized treatments are currently being tested against heterogeneous cancers that were previously thought to be one illness. Our Targeted Therapeutics Team focuses solely on these emerging treatments, such as biomarker-driven therapies, biosimilars, antibody drug conjugates, and other small molecules.

These new therapy approaches necessitate a thorough therapeutic understanding as well as extensive expertise with various therapeutic goals.

Our clinical experts are presently supporting novel approaches to precision medicine in solid tumors, working with cutting-edge medicines such as combination immunotherapies and sophisticated research designs at every stage.